{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:12:19Z","timestamp":1787836339624,"version":"build-2784847793"},"reference-count":51,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FONDO-COVID19","award":["07.04.467804.74011.0"],"award-info":[{"award-number":["07.04.467804.74011.0"]}]},{"name":"FEDER and the Junta of Castilla-Leon","award":["07.04.467804.74011.0"],"award-info":[{"award-number":["07.04.467804.74011.0"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Coronavirus 2019 disease (COVID-19) represents one of the largest pandemics the world has faced, and it is producing a global health crisis. To date, the availability of drugs to treat COVID-19 infections remains limited to supportive care although therapeutic options are being explored. Some of them are old strategies for treating infectious diseases. convalescent plasma (CP) therapy has been used successfully in other viral outbreaks in the 20th century. In this study, we systematically evaluated the effect and safety of CP therapy on hospitalized COVID-19 patients. A structured search was conducted following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines using Medline (PubMed), SciELO, Cochrane Library Plus, Web of Science, and Scopus. The search included articles published up to January 2022 and was restricted to English- and Spanish-language publications. As such, investigators identified six randomized controlled trials that met the search criteria. The results determined that in hospitalized COVID-19 patients the administration of CP therapy with a volume between 200\u2013500 mL and a single transfusion performed in 1\u20132 h, compared to the control group, decreased viral load, symptomatology, the period of infection, and mortality, without serious adverse effects. CP did influence clinical outcomes and may be a possible treatment option, although further studies will be necessary.<\/jats:p>","DOI":"10.3390\/pharmaceutics14051020","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:30:28Z","timestamp":1652142628000},"page":"1020","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Convalescent Plasma Therapy, Therapeutic Formulations of Repurposed Drugs in 20th Century Epidemics against COVID-19: A Systematic Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6522-8896","authenticated-orcid":false,"given":"Diego","family":"Fern\u00e1ndez-L\u00e1zaro","sequence":"first","affiliation":[{"name":"Department of Cellular Biology, Histology and Pharmacology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42003 Soria, Spain"},{"name":"Neurobiology Research Group, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Dom\u00ednguez","family":"Ortega","sequence":"additional","affiliation":[{"name":"Heamtology Service of the Santa B\u00e1rbara Hospital, Castille and Leon Health (SACyL), 42003 Soria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"S\u00e1nchez-Serrano","sequence":"additional","affiliation":[{"name":"Department of Cellular Biology, Histology and Pharmacology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42003 Soria, Spain"},{"name":"Microbiology Unit of the Santa B\u00e1rbara Hospital, Castille and Leon Health (SACyL), 42003 Soria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahd","family":"Beddar Chaib","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Radiology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42003 Soria, Spain"},{"name":"Emergency Service of the Santa B\u00e1rbara Hospital, Castille and Leon Health (SACyL), 42003 Soria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jerves Donoso","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Radiology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42003 Soria, Spain"},{"name":"Neumology Service of the Santa B\u00e1rbara Hospital, Castille and Leon Health (SACyL), 42003 Soria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Jim\u00e9nez-Callejo","sequence":"additional","affiliation":[{"name":"Preventive Medicine Service of the Santa B\u00e1rbara Hospital, Castille and Leon Health (SACyL), 42003 Soria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saray","family":"Rodr\u00edguez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42003 Soria, Spain"},{"name":"Internal Medicine Service of the Santa B\u00e1rbara Hospital, Castille and Leon Health (SACyL), 42003 Soria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-L\u00e1zaro, D., S\u00e1nchez-Serrano, N., Mielgo-Ayuso, J., Luis Garc\u00eda-Hern\u00e1ndez, J., Gonz\u00e1lez-Bernal, J.J., and Seco-Calvo, J. (2021). Long COVID a New Derivative in the Chaos of SARS-CoV-2 Infection: The Emergent Pandemic?. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245799"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36300\/remasp.2020.070","article-title":"Estandarizaci\u00f3n de Emergencia para el Diagn\u00f3stico del virus SARS-CoV-2 mediante la Reacci\u00f3n en Cadena de la Polimerasa de Transcripci\u00f3n Reversa en Tiempo Real (RT-PCR) en situaci\u00f3n de pandemia de COVID-19","volume":"4","year":"2020","journal-title":"Rev. Madrile\u00f1a Salud P\u00fablica"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-L\u00e1zaro, D., and Garrosa, M. (2021). Identification, Mechanism, and Treatment of Skin Lesions in COVID-19: A Review. Viruses, 13.","DOI":"10.3390\/v13101916"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"698672","DOI":"10.3389\/fimmu.2021.698672","article-title":"Glycophosphopeptical AM3 Food Supplement: A Potential Adjuvant in the Treatment and Vaccination of SARS-CoV-2","volume":"12","author":"Adams","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.crphar.2021.100064","article-title":"The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response","volume":"2","author":"Migo","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_6","unstructured":"Centers for Disease Control and Prevention (2022, January 16). Vaccines for COVID-19|CDC, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/index.html."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41231-021-00104-2","article-title":"Vaccination against SARS-CoV-2: A human enhancement story","volume":"6","author":"Carbon","year":"2021","journal-title":"Transl. Med. Commun."},{"key":"ref_8","unstructured":"(2022, January 27). COVID-19 Map\u2014Johns Hopkins Coronavirus Resource Center. Available online: https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"106054","DOI":"10.1016\/j.ijantimicag.2020.106054","article-title":"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A global pandemic and treatment strategies","volume":"56","author":"Sharma","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","first-page":"1824","article-title":"Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jmii.2020.02.001","article-title":"Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV","volume":"53","author":"Lee","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102554","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in Covid-19: Possible mechanisms of action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.2020.4940","article-title":"Convalescent Plasma to Treat COVID-19: Possibilities and Challenges","volume":"323","author":"Roback","year":"2020","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tracli.2015.12.003","article-title":"Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow","volume":"23","author":"Garraud","year":"2016","journal-title":"Transfus. Clin. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-L\u00e1zaro, D., Gonz\u00e1lez-Bernal, J.J., S\u00e1nchez-Serrano, N., Navascu\u00e9s, L.J., Del R\u00edo, A.A., and Mielgo-Ayuso, J. (2020). Physical Exercise as a Multimodal Tool for COVID-19: Could It Be Used as a Preventive Strategy?. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17228496"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"ref_20","first-page":"CD013600","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A living systematic review","volume":"7","author":"Piechotta","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_21","unstructured":"(2022, January 27). China NHC of the PR of Diagnosis and Treatment of COVID-19 (Trial 8th Edition), Available online: http:\/\/www.nhc.gov.cn\/yzygj\/s7653p\/202008\/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.18176\/archmeddeporte.00017","article-title":"Intradialytic physical exercise in chronic kidney disease: A systematic review of health outcomes","volume":"37","year":"2020","journal-title":"Arch. Med. Deporte"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., G\u00f8tzsche, P.C., Ioannidis, J.P.A., Clarke, M., Devereaux, P.J., Kleijnen, J., and Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med., 6.","DOI":"10.2427\/5768"},{"key":"ref_24","unstructured":"Law, M., Stewart, C., Pollock, N., Letts, L., Bosch, J., and Westmorland, M. (1998). Guidelines for Critical Review of Qualitative Studies, McMaster University Occupational Therapy Evidence-Based Practice Research Group."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","article-title":"Convalescent plasma treatment of severe COVID-19: A propensity score\u2013matched control study","volume":"26","author":"Liu","year":"2020","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","article-title":"Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019","volume":"222","author":"Zeng","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early High-Titer Plasma Therapy to Prevent Severe COVID-19 in Older Adults","volume":"384","author":"Libster","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A Randomized Trial of Convalescent Plasma in COVID-19 Severe Pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"ref_30","first-page":"357","article-title":"The therapeutic potential of convalescent plasma therapy on treating critically ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad","volume":"28","author":"Rasheed","year":"2020","journal-title":"Infez. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cmi.2020.08.005","article-title":"Treatment of COVID-19 with convalescent plasma: Lessons from past coronavirus outbreaks","volume":"26","author":"Wooding","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"Bloch","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/hematology.2021000299","article-title":"Passive immune therapies: Another tool against COVID-19","volume":"1","author":"Estcourt","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"key":"ref_34","unstructured":"US Food and Drug (2022, January 20). Recommendations for Investigational COVID-19 Convalescent Plasma|FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/investigational-new-drug-applications-inds-cber-regulated-products\/recommendations-investigational-covid-19-convalescent-plasma."},{"key":"ref_35","unstructured":"Venkateswaran, T.V.S.J. (2022, January 27). India to Explore Novel Blood Plasma Therapy for COVID-19\u2014The Hindu BusinessLine, Available online: https:\/\/www.thehindubusinessline.com\/news\/science\/india-to-explore-novel-blood-plasma-therapy-for-covid-19\/article31311466.ece."},{"key":"ref_36","first-page":"40","article-title":"Current status of treatments for COVID-19","volume":"28","author":"Llover","year":"2021","journal-title":"FMC"},{"key":"ref_37","unstructured":"Diariofarma (2022, January 27). EU Earmarks 36 Million for Projects to Collect Plasma from Convalescent Patients Recovered from COVID-19|@diariofarma. Available online: https:\/\/www.diariofarma.com\/2021\/01\/11\/la-ue-destina-36-millones-a-proyectos-para-recoger-plasma-de-convalecientes-recuperados-de-covid-19."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"107262","DOI":"10.1016\/j.intimp.2020.107262","article-title":"Convalescent plasma may be a possible treatment for COVID-19: A systematic review","volume":"9","author":"Wang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e21596","DOI":"10.1097\/MD.0000000000021596","article-title":"Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.mayocp.2020.06.028","article-title":"Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients","volume":"95","author":"Joyner","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4329\/wjr.v12.i7.137","article-title":"Convalescent plasma therapy in a pregnant COVID-19 patient with a dramatic clinical and imaging response: A case report","volume":"12","author":"Jafari","year":"2020","journal-title":"World J. Radiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment with Convalescent Plasma for Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/jmv.25961","article-title":"Convalescent plasma transfusion for the treatment of COVID-19: Systematic review","volume":"92","author":"Rajendran","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1111\/j.1537-2995.2012.03663.x","article-title":"Adverse effects of plasma transfusion","volume":"52","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41392-020-00301-9","article-title":"Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.mayocp.2021.02.008","article-title":"The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis","volume":"96","author":"Klassen","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2225","DOI":"10.1002\/rmv.2225","article-title":"Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics","volume":"31","author":"Aviani","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Axfors, C., Janiaud, P., Schmitt, A.M., van\u2019t Hooft, J., Smith, E.R., Haber, N.A., Abayomi, A., Abduljalil, M., Abdulrahman, A., and Acosta-Ampudia, Y. (2021). Association between convalescent plasma treatment and mortality in COVID-19: A collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06829-7"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.bja.2021.07.033","article-title":"Convalescent plasma for COVID-19: A meta-analysis, trial sequential analysis, and meta-regression","volume":"127","author":"Snow","year":"2021","journal-title":"Br. J. Anaesth."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e2147331","DOI":"10.1001\/jamanetworkopen.2021.47331","article-title":"Association of Convalescent Plasma Treatment with Clinical Status in Patients Hospitalized with COVID-19: A Meta-analysis","volume":"5","author":"Troxel","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_51","first-page":"1","article-title":"Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab","volume":"29","author":"Bacova","year":"2022","journal-title":"Clin. Exp. Med."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/5\/1020\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:08:21Z","timestamp":1760137701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/5\/1020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["pharmaceutics14051020"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14051020","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]}}}